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46 cases in which the diagnosis was determined with only cytology, 9 
cases were different in diagnosis between cytology and pathology. Sev-
en cases were different only in cell typing of primary lung cancer. One 
case diagnosed as primary lung cancer by cytology was diagnosed as 
metastatic lung cancer from colon cancer by pathology. The other case 
diagnosed as metastatic lung cancer from breast cancer was diagnosed 
as primary lung cancer by pathology. There were no false positive cases 
regarding malignancy.
Conclusion: These results suggest that intra-operative FNA cytology 
with the modiﬁed Shorr’s staining method is useful for diagnosing 
malignancy-suspected pulmonary nodules in clinical practice.
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Introduction: A few prospective studies concerning diagnosis and 
treatment of large cell neuroendocrine lung cancer were published, as 
this tumor seems relatively rare. The objectives of GFPC 03-02 pro-
spective study were to establish the efﬁciency of Cisplatinum /Etopo-
side chemotherapy and to valid value of large spectrum cytokeratins in 
the diagnosis of neuro-endocrine differnciation.
Methods: Patients with stage IV and stage III B (with neoplasic pleural 
effusion) were included; treatment consisted in three cycles of Cisplati-
num 80mg/m2 d1 / Etoposide 100mg/m2 d1d2d3 and two more cycles 
in case of objective response or stable disease.
The primary objective is the efﬁciency of this chemotherapy, second-
ary objective the validation of the paranuclear granular expression of 
a large spectrum cytokeratin, as a characteristic of neuro-endocrine 
differentiation. Slides were controlled by a panel of pathologists. Diag-
noses were based on Travis’s criterias.
Results: 27 patients were included since May 2004. The slides of 21 
cases were reviewed. 14 cases were conﬁrmed as LCNEC. 4 were 
excluded on the basis of the nuclear criteria or cell size, and classiﬁed 
as small-cell carcinomas (SCC). One was excluded, because immuno-
histochemistry was not available. Two other patients were excluded be-
cause of the misinterpretation of the pathologic report by the clinicians 
(one SCC, one Large cell Carcinoma).
Among the 14 cases, two sub-types were observed:
- 8 LCNEC with neuroendocrine features and positive immunohisto-
chemistry
- 6 undifferentiated carcinomas with immunohistochemical neuroen-
docrine differentiation.
None case was diagnosed as large-cell carcinoma with neuroendocrine 
pattern and negative immunohistochemistry.
Table 1. Immunohistochemical results
Antibodies Positive Negative Not Evaluated
Cytokeratin (AE1/AE3 or KL1 or MNF116) 5 2 7
Chromogranin A 12 0 2
Synaptophysin 12 0 2
CD56 6 3 5
TTF1 7 2 5
In all cases, at least two of the three neuroendocrine markers (chromo-
granin A, synaptophysin, CD56) were positive.
Discussion: Interobserver variability is not observed on the criterias 
of neuroendocrine immunohistochemical differentiaton, but only on 
the criterias of size. Some small scratched samples led to difﬁculties to 
distinguish small-cell carcinoma from large-cell carcinoma, especially 
when neuroendocrine morphology (rosettes, trabecular growth pat-
tern,…) was not present. It seems necessary to deﬁnite how many of 
the Travis’s criterias are necessary to accept the diagnosis of LCNEC 
(cell size, chromatin, nucleoli, nuclear-to-cytoplasmic ratio, large and 
eosinophilic or granular cytoplasm) when neuroendocrine differen-
tiation is proved. This interobserver variability is described in the 
literature (1).
Value of the paranuclear granular expression with Cytokeratins must be 
evaluated on cases not yet tested.
Conclusion: Panel of pathologists is useful to diagnose LCNEC. Dis-
agrements were on cell size, some LCNEC were reclassiﬁed as SCC. 
Usefulness of cytokeratins needs some more patients tested.
(1) W.D.Travis, A.A. Gal, T.V. Colby and coll. Reproductibility of neu-
roendocrine lung tumor classiﬁcation. Hum Pathol 1998, 29: 272-279
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Stromal invasion of cancer is associated with proliferation of stromal 
myoﬁbroblasts. These cells are considered as activated ﬁbroblasts that 
facilitate invasion and metastasis of cancer cells. Myoﬁbroblasts in ear-
ly lung adenocarcinoma lesions, such as pure bronchiolo-alveolar carci-
noma (BAC) and mixed type adenocarcinoma with a BAC component, 
are not well documented in the literature. We report here the presence 
of subepithelial myoﬁbroblasts in pure bronchiolo-alveolar carcinoma 
(BAC) and a subset of invasive lung adenocarcinomas. We also charac-
terized their immunohistochemical proﬁles, investigated their relation-
ships with stromal invasion and the prognostic signiﬁcance.
Materials and Methods: A total of 75 cases of surgically resected lung 
adenocarcinomas were examined. There were 9 cases of BAC, 14 cases 
of mixed type adenocarcinoma with a BAC component, and 52 cases 
of pure invasive adenocarcinomas. All cases were immunostained for 
smooth muscle α-actin to visualize myoﬁbroblasts. Selected cases were 
also stained for calponin, desmin and h-caldesmon. 
Results: In all cases of pure BACs, we could observe subepithelial 
myoﬁbroblasts. These cells were characterized by their peculiar loca-
tion between cancer cells and alveolar septa. Immunohistochemically, 
they were positive for smooth muscle α-actin and calponin. Some were 
